Navigation Links
Cipla launches 3-in-1 AIDS drug in India

Cipla has launched an innovative combination of 3 HIV/AIDS drugs, Viraday that needs to be taken just once a day for effective treatment. //

The three anti-HIV drugs efavirenz 600 mg, tenofovir 300 mg and emtricitabine 200mg comprise the drug Viraday. Viraday, one tablet of which alone effectively treats a HIV infected person, eliminates the need for 3 separate medicines. This drug has some advantages like, it is less burdensome and it can be taken along with tuberculosis medicine, which could not be done previously.

This combination drug, that was previously available only in the U.S. and European countries, was first launched in India by Cipla on Thursday. In the U.S. and Europe this combination drug costs Rs. 52,800 a month, whereas Cipla will make it accessible at just Rs. 5,200 per month. This combination drug is less toxic than when the drugs are taken separately.

This breakthrough would improve the adherence-how faithfully patients stick to the course of treatment advised by the doctor. “This is a vital issue in HIV treatment to prevent the infection from reaching the advanced stage of AIDS,” said senior consultant in Internal Medicine at Indraprastha Apollo Hospital, Dr Nalin Nag. He said, “Viraday is very patient friendly, as it requires just one pill a day and freedom from the severe side effect of many other anti HIV drugs.”

The innovative treatment kits and the 3-in-1 pills introduced by Cipla will promote adherence and ease of use. Viraday is the most remarkable accomplishment of Cipla.

Cipla has brought down the price of HIV/AIDS drugs in international market. It supplies HIV/AIDS drugs to majority of African, South Asian, Latin American and several other developing countries.
YT
'"/>




Page: 1

Related medicine news :

1. Cipla holds talks with mining giant to supply AIDS drugs for South African workers
2. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
3. Cipla In India Can Manufacture Drug For Bird Flu
4. FDA Gives Preliminary Nod To Cipla And Sun Drugs
5. Ciplas HIV Drug Gets FDA Approval
6. Glaxo launches pills to help smokers quit in 7-12 weeks
7. Dr Reddy’s Laboratories launches Hyalosy
8. GlaxoSmithKline launches diabetes and cancer drugs
9. YSR launches Operation Dengue
10. Is Diabetes the Leading Cause of Kidney Failure in India
11. AIDS Disaster in India is Imminent

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cipla launches AIDS drug India

(Date:11/8/2009)...lutions is pleased to announce that it has been su...or ReSound who recently received an award on the $...ward includes not only the Veterans Administration...eral agencies. , New York...ns is pleased to announce that it has been success...
(Date:11/8/2009)...battle is won," said Dr. Charmaine Yoest. ,, W...vote of 240-194, the Stupak-Ellsworth-Pitts-Kaptur...bortion mandates and funding in HR 3962 passed on ...ction President and CEO Dr. Charmaine Yoest said, ...e pro-life Americans across this country who have ...
(Date:11/8/2009)...SNewswire/ -- The following was released today by ...ta Nex. ,, Mr. Terry and his associates from a...-killing by abortion out of any health care bill f...t first step to victory -- a touchdown in the firs...f us. Our rejoicing must be tempered by reality. T...
(Date:11/7/2009)...SNewswire/ -- Karen Ignagni, President and CEO of ...the following statement today on House passage of ...mprehensive health care reform, and we have contri...verhaul of how health insurance is provided. Earli...mination of pre-existing condition exclusions, no ...
(Date:11/7/2009)...Calling this a "defining moment" for the American ...mes Rohack, M.D., today addressed medical students...specialty societies at the opening of the AMA,s se...em reform will top the agenda. ,, (Logo: http... ) ,, "Over the next 72 hours, this AMA House o...
Breaking Medicine News(10 mins):Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 2Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 3Health News:Americans United for Life Action Comments on Passage of Pro-Life Amendment: Bipartisan Pro-life Majority Reflects the Will of the American People 2Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA President Kicks Off AMA Meeting Focused on Health Reform 2
...arhers have found from a long-term study that men ...s more likely to eventually develop Parkinson's di... of Biostatistics and Statistics at the University...tipation is defined as less than one bowel movemen...
...sure to sunlight may increase the risk of developi... a cloudy or opaque area in the normally transpare...vents light rays from passing through the lens and...d people who were exposed to high levels of sunlig...
...of the leading pharmaceutical industries, Ranbaxy ...-market Ranbaxy’s once-a-day formulation of Ciprof...g Controller General of India’s (DCGIs) approval f... around Rs 310 crore. // Ciprofloxacin is the...
...ing men are at greater risk of developing heart di...earchers.Their findings were published in the Arch...ng relationship" between coronary heart disease an...9% increased chance of getting heart disease. Comp...
...he biggest breakthrough, the incidence of the dise...ation of drugs that keeps blood pressure in check.... years in many countries showed that strokes were ... and heart attacks and consequently deaths. The dr...
...e are many grueling and expensive options to explo... of it being Acupuncture. According to an art... are particularly favour acupuncture because they ...s, hundreds are lost with each menstrual cycle and...
Other Medicine News:
(Date:11/6/2009)...ANGLE PARK, N.C., Nov. 6 Chimerix,...y-available antiviral therapeutics to address life...velopment of the company,s lead antiviral compound...nd the Global Health Security Initiative (GHSI). ...eveloped for the treatment of smallpox, as well as...
(Date:11/6/2009)...ov. 6 California American Water ha...rugs Down the Drain" week for its San Diego County...ored by public and private agencies alike toward t...tion in our source water supplies. ,, Californi...encouraged to drop off expired or unwanted pharmac...
(Date:11/5/2009)...rio, Nov. 5 Helix BioPha...ed today that its Phase II trial of Topical Interf...ts (AGW) has completed patient enrollment, with th...rial. ,, The double-blind and placebo-controlle...n Germany and Sweden. Patients participating in t...
Breaking Medicine Technology:Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 2Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 3California American Water Celebrates 'No Drugs Down the Drain' Week in San Diego 2Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 2Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 3Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 4Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 5Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 6Letter to Shareholders From Imagenetix Inc President CEO William Spencer 4902 1Letter to Shareholders From Imagenetix Inc President CEO William Spencer 4902 2Letter to Shareholders From Imagenetix Inc President CEO William Spencer 4902 3Letter to Shareholders From Imagenetix Inc President CEO William Spencer 4902 4Letter to Shareholders From Imagenetix Inc President CEO William Spencer 4902 5A better test to detect DNA for diagnosing diease investigating crimes 55405 1Rutgers Camden developing enzyme function database 9702 1Rutgers Camden developing enzyme function database 9702 2
... FRANCISCO, Calif., July 9 Portola,Pharmaceutical...cused on,the discovery and development of novel th...eases, announced today that is has raised $60 mill...be used primarily to advance,Portola,s two lead an...RT060128, which the company is developing as best-...
... FRANCISCO, July 9 Cerimon Pharmaceuticals,Inc., ...of-concept study of,Simulect(R) (basiliximab) for ...and potentially sight-threatening inflammation of ...ntrolled study will evaluate the,safety and effica...ts.,During the study, patients will undergo taperi...
Other Medicine Technology:Portola Completes $60 Million Financing to Advance Its Therapeutic Programs 2Portola Completes $60 Million Financing to Advance Its Therapeutic Programs 3Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis 2
AxSYM
ADVIA Centaur Immunoassay System
...linical system combines market-leading chemistry a...y testing capabilities, innovative data management...m. After tests are performed, critical results are...nce. If reflex tests are necessary based on user d...
Miltex frazier ferguson suction tubes
Medicine Products: